Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome.
Spiriti MA, Latagliata R, Niscola P, Cortelezzi A, Francesconi M, Ferrari D, Volpe E, Clavio M, Grossi A, Reyes MT, Musto P, Mitra ME, Azzarà A, Pagnini D, D'Arena G, Spadano A, Balleari E, Pecorari P, Capochiani E, De Biasi E, Perego D, Monarca B, Pisani F, Scaramella G, Petti MC.
Spiriti MA, et al. Among authors: niscola p.
Ann Hematol. 2005 Mar;84(3):167-76. doi: 10.1007/s00277-004-0961-9. Epub 2004 Nov 30.
Ann Hematol. 2005.
PMID: 15592833
Clinical Trial.